Price
Financials
Standalone, Rs crore| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 9.27 | 126.43 | 42.14 | 12.61 |
| Expenses | 10.65 | 100.65 | 31.12 | 13.21 |
| Operating Profit | -1.38 | 25.78 | 11.02 | -0.60 |
| OPM % | -14.89% | 20.39% | 26.15% | -4.76% |
| Other Income | 0.28 | 0.31 | 0.19 | 0.29 |
| Interest | 1.15 | 2.03 | 2.03 | 1.61 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.05 |
| Profit before tax | -2.30 | 24.01 | 9.13 | -1.97 |
| Tax % | -24.78% | 25.70% | 25.96% | -12.18% |
| Net Profit | -1.73 | 17.84 | 6.76 | -1.72 |
| EPS in Rs | -0.91 | 9.37 | 3.55 | -0.90 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 12.23 | 25.93 | 35.00 | 78.12 | 65.16 | 135.71 | 54.75 |
| Expenses | 10.64 | 23.52 | 24.95 | 68.67 | 58.81 | 111.31 | 44.34 |
| Operating Profit | 1.59 | 2.41 | 10.05 | 9.45 | 6.35 | 24.40 | 10.41 |
| OPM % | 13.00% | 9.29% | 28.71% | 12.10% | 9.75% | 17.98% | 19.01% |
| Other Income | 0.09 | 0.08 | 0.04 | 0.21 | 0.46 | 0.59 | 0.49 |
| Interest | 0.90 | 0.87 | 0.14 | 2.08 | 2.11 | 3.18 | 3.64 |
| Depreciation | 0.07 | 0.09 | 0.02 | 0.08 | 0.09 | 0.09 | 0.09 |
| Profit before tax | 0.71 | 1.53 | 9.93 | 7.50 | 4.61 | 21.72 | 7.17 |
| Tax % | 8.45% | 43.79% | 24.87% | 27.33% | 24.30% | 25.78% | 29.71% |
| Net Profit | 0.65 | 0.86 | 7.46 | 5.45 | 3.49 | 16.12 | 5.04 |
| EPS in Rs | 10.66 | 3.89 | 2.49 | 8.47 | 2.65 | ||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 16% | -11% | -60% | ||
| Compounded Profit Growth | % | 42% | -3% | -69% | ||
| Stock Price CAGR | % | % | % | -62% | ||
| Return on Equity | % | 24% | 19% | 8% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.74 | 4.34 | 7.00 | 14.00 | 14.00 | 19.04 | 19.04 |
| Reserves | 0.00 | 0.00 | 7.45 | 5.93 | 9.40 | 45.22 | 50.30 |
| Borrowings | 4.03 | 1.48 | 13.69 | 28.74 | 42.05 | 30.34 | 7.12 |
| Other Liabilities | 6.21 | 5.09 | 20.49 | 13.21 | 10.19 | 49.36 | 5.40 |
| Total Liabilities | 13.98 | 10.91 | 48.63 | 61.88 | 75.64 | 143.96 | 81.86 |
| Fixed Assets | 0.69 | 0.63 | 1.54 | 1.49 | 1.43 | 1.38 | 1.39 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
| Other Assets | 13.29 | 10.28 | 47.09 | 60.39 | 74.21 | 142.58 | 80.12 |
| Total Assets | 13.98 | 10.91 | 48.63 | 61.88 | 75.64 | 143.96 | 81.86 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.06 | 3.58 | 10.41 | -13.49 | -9.97 | -10.64 | 31.48 |
| Cash from Investing Activity | -0.57 | 0.03 | -0.24 | -1.83 | -1.00 | -0.41 | -4.01 |
| Cash from Financing Activity | 0.54 | -3.67 | -7.69 | 13.04 | 11.11 | 10.89 | -27.65 |
| Net Cash Flow | 0.04 | -0.06 | 2.48 | -2.28 | 0.14 | -0.16 | -0.18 |
| Free Cash Flow | -0.31 | 3.55 | 10.38 | -13.52 | -10.58 | -10.89 | 31.31 |
| CFO/OP | 22% | 173% | 149% | -115% | -133% | -28% | 333% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 182.35 | 57.99 | 278.23 | 195.30 | 325.23 | 320.38 | 367.87 |
| Inventory Days | 245.38 | 121.90 | 454.87 | 375.97 | 73.78 | 81.04 | |
| Days Payable | 268.89 | 146.76 | 1,099.89 | 414.62 | 145.83 | 95.38 | |
| Cash Conversion Cycle | 158.84 | 33.13 | -366.78 | 156.66 | 253.19 | 320.38 | 353.53 |
| Working Capital Days | 39.69 | 36.32 | 199.92 | 116.43 | 152.76 | 165.60 | 377.40 |
| ROCE % | 35.32% | 59.31% | 24.94% | 11.78% | 31.12% | 12.64% |
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Promoters | 73.53% | 73.53% | 73.53% | 74.05% |
| FIIs | 2.47% | 0.41% | 0.00% | 0.00% |
| DIIs | 5.38% | 0.72% | 0.77% | 0.70% |
| Public | 18.62% | 25.34% | 25.70% | 25.24% |
| No. of Shareholders | 749 | 628 | 822 | 933 |
Fundamentals
Market Cap₹ 200 Cr.
Current Price₹ 105
Stock P/E39.7
Book Value₹ 36.4
ROCE12.6 %
ROE7.54 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-60%
Compounded Profit Growth (TTM)-69%
Standalone figures.
Valuation
Market capRs 143 Cr
Enterprise valueRs 171 Cr
P/E (TTM)26.20x
Price to book7.17x
Price to sales1.83x
EV / EBITDA17.67x
EV / EBIT17.82x
EV / sales2.18x
Earnings yield3.82%
Profitability
Operating margin (excl. other income)12.10%
Operating margin (incl. other income)12.37%
EBITDA margin12.37%
Pre-tax margin9.60%
Net profit margin6.98%
ROE31.70%
ROCE24.94%
ROA9.86%
ROE, 3-year average41.67%
ROCE, 3-year average30.36%
ROA, 3-year average13.94%
ROIC (approx.)14.56%
Tax rate27.33%
Other income / net worth1.05%
Growth
Sales growth (latest year)123.20%
Profit growth (latest year)-26.94%
Sales CAGR, 3 years85.54%
Profit CAGR, 3 years103.16%
Per share
EPS (TTM)Rs 3.89
EPS (latest year)Rs 3.89
EPS, 3-year averageRs 5.51
Book value per shareRs 14.24
Sales per shareRs 55.80
Cash flow per shareRs -9.64
Free cash flow per shareRs 22.36
Efficiency
Asset turnover1.26x
Fixed asset turnover52.43x
Inventory turnover1.12x
Inventory days325 days
Debtor days195 days
Debtors turnover1.87x
Creditor days95 days
Cash conversion cycle354 days
Working capital days377 days
Leverage
Total debtRs 29 Cr
Cash and bankRs 1 Cr
Net debtRs 28 Cr
Debt to equity1.44x
Net debt / EBITDA2.89x
Interest coverage4.61x
Owners' fund to total sources32.21%
Debt to assets46.44%
Cash flow
Cash from Operating Activity (latest year)Rs -13 Cr
Cash from Investing Activity (latest year)Rs -2 Cr
Cash from Financing Activity (latest year)Rs 13 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs 31 Cr
FCFE (approx.: FCF + change in debt)Rs 46 Cr
Cash from ops / profit, 5 years0.21x
Statement figures
Net sales (TTM)Rs 78 Cr
Net sales (latest year)Rs 78 Cr
Operating profit excl. other income (latest year)Rs 9 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 10 Cr
PBDT (TTM)Rs 8 Cr
Profit before tax (TTM)Rs 8 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 5 Cr
Net profit (latest year)Rs 5 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 9 Cr
Total expenditure (latest year)Rs 69 Cr
Total income (latest year)Rs 78 Cr
Share capitalRs 14 Cr
ReservesRs 6 Cr
Shareholders' fundsRs 20 Cr
Total assetsRs 62 Cr
Net blockRs 1 Cr
ReceivablesRs 42 Cr
InventoryRs 8 Cr
Other liabilitiesRs 13 Cr
Shares outstanding (crore)1.40
Ownership
Promoter holding74.05%
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 26.2 is the lowest in its own 2.2-year history
(median 51.1, low 26.2, high 265.8).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | APRAMEYA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +2.8% | -2.8% | +5.6 pts |
| 1 month | -19.4% | -6.8% | -12.6 pts |
| 3 months | -34.2% | -7.6% | -26.6 pts |
| 6 months | -53.1% | +0.4% | -53.5 pts |
| 1 year | -63.4% | -9.9% | -53.5 pts |
| 2 years | +32.5% | -13.6% | +46.0 pts |
Red flags
F-score 2 of 7| explain | Weak cash conversion Cash from operations was 4% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 31% of total assets in 2026 |
| explain | Debt up, profit down Borrowings up 110% while net profit fell in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
| Vaidya Sane Ayurved Laboratories Ltd | 176 | 19.6 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 monthsHigh low price variation greater than 150perc in previous 12 monthsHigh low price variation greater than 200perc in previous 365 DaysLess than 100 unique PAN traded in previous 30 daysSME scrip is not regularly traded
Quick answers
What is the market cap of Aprameya Engineering Ltd?
Aprameya Engineering Ltd (APRAMEYA) has a market capitalisation of Rs 200 Cr. at the 2026-10-01 close.
What is the P/E ratio of Aprameya Engineering Ltd?
Aprameya Engineering Ltd trades at a P/E of 39.7 on trailing twelve-month profit, at the 2026-10-01 close.
What is the 52-week high and low of Aprameya Engineering Ltd?
The 52-week high is Rs 360.00 and the 52-week low is Rs 94.95.